Towards translational ImmunoPET/MR imaging of invasive Pulmonary Aspergillosis: The Humanized Monoclonal Antibody JF5 detects Aspergillus Lung Infections in Vivo
Invasive pulmonary aspergillosis…
Fusion Antibodies announces partnership with Protein Alternatives to develop world class humanized antibodies for therapeutic development
Fusion Antibodies plc, a UK-based contract research organisation and Protein Alternatives,…
Non-phosphorylated and Phosphorylated Signal Transduction Peptide (STP) of Tissue Factor (TF) in Urine are Potential Biomarkers for Bladder and Colon Cancer.
Tissue factor (TF, CD142) is commonly associated with the initiation…
/wp-content/uploads/2022/01/fusion-antibodies-logo.svg00Jack Abraham/wp-content/uploads/2022/01/fusion-antibodies-logo.svgJack Abraham2018-05-23 10:43:442022-04-05 10:48:26Potential biomarkers for bladder and colon cancer
Queen’s University Belfast researchers at the Centre for Cancer Research and Cell Biology (CCRCB) alongside Fusion Antibodies plc have secured a prestigious Medical Research Council (MRC) award to develop a new antibody drug for the treatment…
/wp-content/uploads/2022/01/fusion-antibodies-logo.svg00Jack Abraham/wp-content/uploads/2022/01/fusion-antibodies-logo.svgJack Abraham2018-05-15 10:51:342022-04-05 10:48:29Funding for Queen’s pancreatic cancer drug research in collaboration with Fusion Antibodies
Fusion Antibodies has announced plans to create 28 new jobs. This recruitment drive, supported by Invest NI, will help Fusion Antibodies deliver its services to its growing international customer base.
Invest NI has offered Fusion Antibodies…
/wp-content/uploads/2022/01/fusion-antibodies-logo.svg00Jack Abraham/wp-content/uploads/2022/01/fusion-antibodies-logo.svgJack Abraham2018-05-10 10:47:292022-04-05 10:48:36Fusion Antibodies to double workforce with help from Invest NI
We are delighted to showcase the progress of Phase 1 of our ambitious expansion project that is now well underway.
As many of you will remember, in December 2017 Fusion Antibodies became one of only three companies in Northern Ireland…
Fusion Antibodies have been shortlisted for a category at the 2018 Northern Ireland Dealmakers Awards
Fusion Antibodies are absolutely delighted to be shortlisted in the Deal of the Year (£2.5m - £10m) award category in the Insider…
/wp-content/uploads/2022/01/fusion-antibodies-logo.svg00Jack Abraham/wp-content/uploads/2022/01/fusion-antibodies-logo.svgJack Abraham2018-02-13 11:05:032022-04-05 10:48:47We have made the 2018 NI Dealmakers Awards shortlist!
We're delighted to announce that we have some new services launching in 2018!
Developability and Manufacturability Services!
We have developed a range of software analytics delving into the properties of antibodies. These…
Fusion Antibodies to seek AIM IPO
We are delighted to announce that we are seeking a listing on the AIM Market of the London Stock Exchange and has published its AIM Admission Document which will be available to view here.
/wp-content/uploads/2022/01/fusion-antibodies-logo.svg00Jack Abraham/wp-content/uploads/2022/01/fusion-antibodies-logo.svgJack Abraham2017-12-15 11:23:082022-04-05 10:48:54Fusion to become third Northern Irish Company listed on the London Stock Exchange
Fusion Antibodies are pleased to be attending PEGS Europe being held on 13-17th November in Lisbon, Portugal.
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. Last year, in 2016, a record…
/wp-content/uploads/2022/01/fusion-antibodies-logo.svg00Jack Abraham/wp-content/uploads/2022/01/fusion-antibodies-logo.svgJack Abraham2017-11-15 11:28:352022-04-05 10:48:59Fusion Antibodies are attending PEGS Europe
Fusion Antibodies are delighted to be attending BioFIT being held on 28-29th November in Strasbourg, France.
BioFIT is the leading partnering event in Europe fortechnology transfer, academia-industry collaborations and early-stage…
Fusion Antibodies are attending BioJapan 2017 Pharma Event
Fusion Antibodies are pleased to be attending BioJapan 2017 being held on 11-13th October in Pacifico Yokohama, Japan.
Chris Moriarty from the Fusion Team will be showcasing…
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Other external services
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: